TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With Stabilized Transthyretin (TTR Tetramer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-2 microglobulin levels as an indicator of HAART failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Commonly Reported and Notable Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Treatment Engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stigma
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in absolute haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Fixation control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Evoked Potential amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Technical performance of CLA-EUS versus FV-EUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatic Symptoms Scale-8 (SSS-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: all cause mortality at one year
Endpoint domain: Mortality/survival
Primary endpoint: score on a depression rating scale at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in NCIC-CTC 4.0 scale from baseline
Endpoint domain: Adverse events/effects
Primary endpoint: change in general and disease-specific symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in HIV proviral DNA in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vitamin C plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin C excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Plantar fascia thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in CIBIC-Plus Global Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in ADCS-ADLsev-abv
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment response status at week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response status at week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of initial wound size area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Excess Weight Loss (EWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HCV RNA Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of PEG liposomes in atherosclerotic plaque and macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: International Normalized Ratio level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron Depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Systemic Lupus Activity Questionnaire global health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: risk of hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: Specificity of RHEA scoring model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of RHEA scoring model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort/Pain for anesthetic injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin resistance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative Incidence of Advanced Cancers
Endpoint domain: Mortality/survival
Primary endpoint: Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUC0-tlast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Completing Interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Psoriatic Assessment Score Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Time-averaged Pain Intensity VAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum concentrations of Eotaxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in serum concentrations of S100B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in expression of TNFSF14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in expression of CCL11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in EQ-5D-3L (EuroQoL 5 Domains evaluated in 3 levels)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short time quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cinematics of eye movements (amplitude and direction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of EVP-6308
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment related events
Endpoint domain: Adverse events/effects
Primary endpoint: AUClast: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for TAK-954
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Detrusor thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing study-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Exhaled Oxygen Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Spent in Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of responders defined by a decrease of at least 50% of the Y-MRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients who experience dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Spike wave index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Posttraumatic Stress Disorder Symptom Scale- Interview Version (PSS-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SARS CoV2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the curve at steady state (AUCss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating behavior measured via grams of food consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First Hospital Readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Performance Assessment-Pain Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in plasma concentrations of progranulin (PGRN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DC-Shift (µV/sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cancer-related Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of curative surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in plasma biomarkers of inflammation and atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative incidence of neurologic clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax and AUC of BAY73-4506
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC of Platinum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC of Irinotecan and SN-38
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and AUC of 5-Fluorouracil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait speed during transitioning from sitting to walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait speed during transitioning from standing to walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pure gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in angina symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tacrolimus AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TIMI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in the KOOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cytokine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Technical Success at Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Closure and Echocardiographic Closure at 12 month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Events and Mortality at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients achieving specific results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression in Interstitial Lung Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of IZD174 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of IZD174 in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of IZD174 concentration in plasma to CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Markers of Endothelial Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of children detected with FH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Vaccination Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Primary Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Booster Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic and Functional Recovery Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first episode of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Eccentric distance of the intraocular lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tilt angle of the intraocular lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality till 5 years of age
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalisations till 5 years of age
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adverse effects within 12 months after intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With a Hemagglutinin Inhibition (HAI) Titer of >=40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IDAA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative measurement system capture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of disease related biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient occurrence of persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperbaric Treatment Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wound Assessment Form Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Assessment Form Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease Free Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: decrease in tumor cell count in IP fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Autonomic Cardiac Modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Refractive Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in Parkinson Disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Child Behavior Rating Scale (CBRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline LDL-cholesterol at 4-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline total cholesterol at 4-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline non-HDL-cholesterol at 4-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Neutralizing antibody titers to SF162 and TV1
Endpoint domain: Physiological/clinical
Primary endpoint: Probability of Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical benefit assessed by RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average deviation in set-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Low-density Lipoprotein (LDL) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in High-density Lipoprotein (HDL) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Visceral Adipose Tissue (VAT) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Fat Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequacy of cytologic specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumour Necrosis Factor Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Restoration of normal glucose regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of Disease or Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in Triglyceride Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mitochondrial cellular energetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulmonary blood flow during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Three-year Relapse-free Survival (RFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean VAS Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in myocardial function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Frequency of Marijuana Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Quantity of Marijuana Use per Occasion of Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of the mobile ECG device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of the mobile ECG device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dark adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to COPD guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Cardiovascular hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Re-hospitalization and death rates
Endpoint domain: Mortality/survival
Primary endpoint: Total hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Satisfaction with Decision at 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with Decision at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With at Most One Day With Not More Than Mild Intensity of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Static postural balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment Emergent Markedly Abnormal Laboratory Values
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Abnormal Vital Sign Values
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Markedly Abnormal Electrocardiogram (ECG) Parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of inhibition in light transmittance aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ekman 60 Faces Test total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hinting Task total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Happé Strange Stories Test total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faux Pas Recognition Test total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambiguous Intentions and Hostility Questionnaire total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movie for the Assessment of Social Cognition total score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Adhering to the Expected Number of Screening Tests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: plasma zinc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: At-risk drinking status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Methylation of HOXA1 and NEUROG1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in the quantity of urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Post-stroke disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful placement of PICC lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Image quality of 23Na-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Engraftment at Day 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes